IGCPharma revolutionizing
Alzheimer's Care
Cannabinoid-based drugs have the potential to improve the lives of millions with Alzheimer’s disease
Alleviating the Debilitating Symptoms
of Alzheimer’s
Our drug candidate, IGC-AD1, has shown promising results in treating agitation in Alzheimer’s patients.
What we do is Important
With no known cure, our formulations have the potential to change lives
Americans with
Alzheimer’s
disease in 2022
Americans with
Alzheimer’s disease
by 2060
5th Leading
Cause of death among
Americans age 65+
Expected cost of Alzheimer’s and dementia by 2050 if no treatment or cure is found
What We Do
is Unique
60-70% of Alzheimer’s patients suffer from debilitating symptoms, such as agitation, anxiety, and depression.
There are no FDA-approved
drugs to treat agitation in Alzheimer’s.
Agitation is emotional distress,
verbal and physical aggression.
It is associated with higher admissions to assisted living
facilities, long-term
hospitalization,
and higher mortality.
IGC-AD1 Phase 1 studies
showed promise to treat
agitation in Alzheimer’s.
IGC-AD1 is the FIRST natural cannabis-based
patent-protected compound
that relies on low doses
of THC and another compound
as active pharmaceutical ingredients (API) for the
treatment of agitation in Alzheimer’s.
The ONLY natural THC-based investigational drug candidate currently undergoing FDA trials registered on clinicaltrials.gov
Major milestones
2013
Development of cannabis-based formulations for neurological disorders such as Alzheimer’s disease, Epilepsy, and Tourette Syndrome.
2015
Filed patents on the use of cannabinoids for pain, seizures, and eating disorders.
2017
Acquired the patent filings for IGC-AD1, a cannabis-based drug for treating Alzheimer’s from the University of South Florida. Development of IGC-AD1.
2019
Filed patents Tourette’s Syndrome, eating disorders, CNS disorders, fatigue and energy restoration. Launched Phase 1 safety and tolerability trial on IGC-AD1
2021
Completed a Phase 1 clinical study on IGC-AD1 to evaluate safety and tolerability in participants with mild to moderate Alzheimer’s disease. Filed patents for compositions and methods for treating pain and for stress relief.
2022
Acquired TGR-63, a molecule developed by the Jawaharlal Nehru Center for Advanced Scientific Research(JNCASR), which demonstrated, in Alzheimer’s cell lines, potential to reduce the plaque associated with Alzheimer’s.
Launched a Phase 2 double-blind, multi-site, clinical trial to evaluate the safety and efficacy of IGC-AD1 on agitation in dementia due to Alzheimer’s disease.
